Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hans M.G. Princen"'
Autor:
E.H. Offerman, Astrid Trion, Arnoud van der Laarse, Wouter Jukema, Moniek P.M. de Maat, Louis M. Havekes, Jef J. Emeis, Annemarie C.E. Maas, Hans M.G. Princen, Alexander J. Szalai
Publikováno v:
Journal of Cardiovascular Pharmacology, 47(1), 89-95. Lippincott Williams & Wilkins
We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/
Autor:
Joyce Chi Yee Chan, Simon Jackson, Hans M.G. Princen, José W.A. van der Hoorn, Scott M. Wasserman, Elsbet J. Pieterman, Brandon Ason, Kathy Nguyen, Susan Shetterly, Mei Di, Margrit Schwarz, J. Wouter Jukema, Jie Tang, Edward Lee, Rob Scott, Wen-Chen Yeh
Publikováno v:
Journal of Lipid Research, 55(11), 2370-2379
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
Journal of Lipid Research, 11, 55, 2370-2379
Journal of Lipid Research, Vol 55, Iss 11, Pp 2370-2379 (2014)
Journal of Lipid Research, 11, 55, 2370-2379
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C clearance. The therapeutic potential for PCSK9 inhibitors is highlighted by the fact that PCSK9 l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39084ecc72a660fcf4dd482ee87539a
https://hdl.handle.net/1887/103264
https://hdl.handle.net/1887/103264
Autor:
Gerwin J. Puppels, J. Wouter Jukema, Sweder W.E van de Poll, Louis M. Havekes, Hans M.G. Princen, Arnoud van der Laarse, Dianne J.M. Delsing
Publikováno v:
Journal of Molecular and Cellular Cardiology, 35(1), 109-118. Academic Press
Combined treatment of statins and calcium channel blockers has been suggested to be superior to statin therapy alone. We quantified the anti-atherosclerotic potential of amlodipine, atorvastatin and their combination on existing atherosclerotic plaqu
Autor:
Gene Liau, Hans M.G. Princen, José W.A. van der Hoorn, Anita M. van den Hoek, J. Wouter Jukema, Louis M. Havekes, Susan Kühnast
Publikováno v:
Journal of Hypertension, 1, 30, 107-116
Journal of Hypertension, 30(1), 107-116
Journal of Hypertension, 30(1), 107-16
Journal of Hypertension, 30(1), 107-116
Journal of Hypertension, 30(1), 107-16
Objective: Aliskiren is the first commercially available, orally active, direct renin inhibitor approved to treat hypertension. The renin-angiotensin system has been shown to be a significant contributor to the development of hypercholesterolemia-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcbe2be8b56e63327af1e3e80f95671b
https://hdl.handle.net/1887/111167
https://hdl.handle.net/1887/111167
Autor:
Hans M.G. Princen, E.H. Offerman, Teake Kooistra, Alexander J. Szalai, Robert Kleemann, Sjef J. Emeis, Lars Verschuren
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 25(1)
Objective - To evaluate whether low-dose atorvastatin suppresses atherosclerotic lesion progression and inflammation in apolipoprotein E*3 (apoE*3)-Leiden mice beyond its cholesterol-lowering effect. Methods and Results - ApoE*3-Leiden mice were fed
Autor:
Ronald P. Mensink, Oscar L. Volger, Gerard Hornstra, Jogchum Plat, L.M. Havekes, Hans M.G. Princen
Publikováno v:
Atherosclerosis, 157, 375-381. Elsevier Ireland Ltd
Atherosclerosis 2001 Aug;157(2):375-81 Related Articles, Books, LinkOut Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice.Volger OL, Mensink RP, Plat J, Hornstr
Autor:
J.W. Jukema, H. van der Boom, L.M. Havekes, E.C.M. de Wit, W. van Duyvenvoorde, E.H. Offerman, Dianne J.M. Delsing, A. van der Laarse, Hans M.G. Princen, Marion J.J. Gijbels
Publikováno v:
Circulation, 13, 103, 1778-1786
Circulation, 103(13), 1778-1786. Lippincott Williams and Wilkins
Scopus-Elsevier
Circulation, 103(13), 1778-1786. Lippincott Williams and Wilkins
Scopus-Elsevier
Background —The present study investigated whether the ACAT inhibitor avasimibe can reduce atherogenesis independently of its cholesterol-lowering effect in ApoE*3-Leiden mice. Methods and Results —Two groups of 15 female ApoE*3-Leiden mice were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a3bde6ac72f3e1f4ad9e3d2dfef3dac
http://resolver.tudelft.nl/uuid:85b365bd-e856-4f9d-aa3d-73b1481a4448
http://resolver.tudelft.nl/uuid:85b365bd-e856-4f9d-aa3d-73b1481a4448